MED Medifast, Inc.
XNYS
12.97
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
MED
$12.97
—
What changed
Recent filings, trades and movesKey stats
$12.97
- 52-Week Range
- $9.22 – $13.63
- YTD
- +24.71%
- IV Rank (30D)
- 48.85
- Straddle Price
- $1.12
- P/C Vol Ratio
- 0.42
- Market Cap
- $0.1B
- Open
- $12.95
- Day Range
- $12.77 – $13.02
- Volume
- 67,335
- Prev Close
- $12.86
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.88% |
| Beta vs SPY | 0.80 |
| Cost of Equity (CAPM) | 8.88% (VRP-adj) |
| WACC | 8.94% |
| Volatility Risk Premium | +75.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -4.1% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -22.7% |
| Book / Price | 125.4% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 69.2% |
| FCF Margin (TTM) | -1.3% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $12.12 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.48 |
| Bollinger Width / SMA20 | 14.3% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: AHR, BKU, BY, CNO, PSTL, SLDE, SPHR, SPSC
Blended Fair Value
$27.71
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 18.9× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 15.1× · 8 peers |
| Peer P/B | $36.84 | 17% | median 2.3× · 8 peers |
| Peer P/S | $81.32 | 17% | median 3.0× · 8 peers |
| Market Anchor (SMA50) | $12.12 | 67% | stability 78% (BB-width) |
| Options Expected (B-L 30d) | $12.74 | 0% | 8 strikes · skew -0.06 |
As of 2026-11-13 · updated
Related
About
- Industry (SIC)
- MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS (2090) · industry map
- Exchange
- XNYS
- Market Cap
- $0.1B
- Employees
- 380
- List Date
- 1981-03-24
- CIK
- 0000910329
- Last Earnings
- Oct 26 before open · +2.0% vs ±10.7% expected
- Headquarters
- Baltimore, MD
- Homepage
- https://www.medifastinc.com
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle S…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 21.84% | -7.93% | -3.17% | -22.18% | -9.20% | 10.00% | -1.77% |
| Feb | 8.78% | -6.36% | -2.50% | -26.79% | -6.27% | -8.43% | -6.93% |
| Mar | -20.31% | -11.42% | -6.05% | -5.24% | -3.85% | -2.39% | -8.21% |
| Apr | 2.15% | 1.15% | -10.58% | -26.61% | 0.00% | 7.62% | -4.38% |
| May | 41.93% | -4.46% | -13.11% | -2.35% | 8.40% | 14.85% | 7.54% |
| Jun | -14.07% | 3.26% | 16.25% | -12.72% | 5.48% | -16.46% | -3.04% |
| Jul | -0.29% | -8.68% | 7.66% | 4.28% | -6.13% | -10.43% | -2.26% |
| Aug | -18.44% | -28.55% | -15.60% | -15.51% | 2.04% | 24.64% | -8.57% |
| Sep | -16.11% | -8.76% | -10.89% | 6.69% | -1.80% | -4.71% | -5.93% |
| Oct | 1.19% | 5.34% | -8.65% | -4.37% | -11.42% | 6.30% | -1.94% |
| Nov | -2.80% | 6.09% | -3.41% | 5.87% | -7.66% | 3.51%* | 0.27% |
| Dec | 4.65% | -4.12% | -1.60% | -11.19% | -0.56% | -- | -2.56% |
| Total | -7.60% | -51.39% | -43.68% | -71.46% | -28.42% | 18.83% | -30.62% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.53
SMA 50: $12.13
SMA 200: $11.38
Current: $12.97
EMA 12: $12.80
EMA 26: $12.50
MACD: 0.3029 | Signal: 0.0372
BULLISH
ADX (14): 31.06
TREND
+DI: 27.53
−DI: 14.00
Momentum Oscillators
RSI (14): 58.61
NEUTRAL
Stoch %K: 63.42
Stoch %D: 69.00
Williams %R: -40.49
Volume & Volatility
BB Upper: $13.41
BB Lower: $11.66
NEUTRAL
OBV: -9,320,800
Vol SMA 20: 136,068
Vol ROC: -70.97%
ATR: $0.44
True Range: $0.25
HV 20: 34.9%
HV 30: 30.2%
HV 60: 29.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-15T00:00:00 – 2026-11-13T00:00:00
AI Analysis
Written before MED’s Oct 26 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: MED
Executive Summary
Overall assessment: NEUTRAL with confidence level (6/10)
Key drivers:
- Technical indicators suggest a consolidating market, with short-term momentum slowing down
- Recent news headlines unavailable, making it difficult to assess sentiment impact
Primary risks:
- Low volatility, which may lead to reduced price movement and trading opportunities
- Bearish MACD signal and declining OBV indicate potential for further price declines
Investment thesis: MED is a consolidating stock with low volatility, potentially setting up for a breakout or breakdown in the near future.
Recent news sentiment impact: No recent news available, making it difficult to assess sentiment impact on the stock's price movement.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Neutral, Medium-term (1-3 months): Uptrend, Long-term (3-12 months): Uptrend
Support/Resistance Levels: SMA 20: $11.30, SMA 50: $12.48, SMA 200: $13.40
Momentum Signals:
- RSI interpretation: Neutral (32.51), no buy/sell signal
- MACD signal: Bearish (bearish crossover above the signal line)
- Bollinger Bands position: Neutral (price touching middle band)
Volume Analysis: Volume trends: Consolidation, institutional interest signals: Low
News & Sentiment Analysis
Recent Headlines Summary: No recent news available
Sentiment Assessment: N/A due to lack of recent news headlines
Catalyst Identification: None identified based on the available data
Market Narrative: The market narrative is neutral due to the absence of significant news headlines.
Risk & Volatility Assessment
Beta Interpretation: Low risk relative to market (beta: 0.49)
Volatility Regime: Current vs historical volatility levels: Low volatility
Options Market Signals: IV rank: High (96.7%), put/call ratios: Bearish, unusual activity: None identified
Downside Protection: Support level: $10.26, risk management considerations: Stop-loss at $9.30
Market Context & Positioning
Sector Performance: MED's sector performance is neutral compared to the overall market.
Institutional Activity: Institutional interest signals are low, indicating reduced buying pressure.
Correlation Analysis: MED moves relatively less than the market (R-squared interpretation: 0.24)
Relative Valuation: MED is positioned within its trading range.
Key Levels & Action Items
Critical Price Levels: Support/resistance levels: SMA 20 ($11.30), SMA 50 ($12.48), SMA 200 ($13.40)
Breakout/Breakdown Levels: None identified based on the available data
Time-Sensitive Catalysts: None identified based on the available data
Risk Management: Stop-loss at $9.30, position sizing considerations: 10-20% of total portfolio
Overall assessment: MED is a consolidating stock with low volatility, potentially setting up for a breakout or breakdown in the near future. Technical indicators suggest a neutral trend direction, and recent news headlines are unavailable. Risk management considerations include stop-loss at $9.30 and position sizing within 10-20% of total portfolio.
Generated
News
All MED news →
Cost cuts and a metabolic health pivot must prove they can reignite growth before cash reserves deplete.
CEO Johnson targets Q4 profitability amid record coach productivity gains.
Earnings History
19 of 24 under expected move
Avg Expected Move
13.57%
Avg Actual Move
8.09%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | After-Close | 15.73% | 0.69% | 0.04x | Within |
| 2021-05-04 | After-Close | 11.37% | 12.12% | 1.07x | Exceeded |
| 2021-08-04 | After-Close | 12.58% | 9.38% | 0.75x | Within |
| 2021-11-04 | After-Close | 13.55% | 2.92% | 0.22x | Within |
| 2022-02-23 | After-Close | 13.03% | 2.00% | 0.15x | Within |
| 2022-05-02 | After-Close | 13.66% | 7.73% | 0.57x | Within |
| 2022-08-03 | After-Close | 10.61% | 13.72% | 1.29x | Exceeded |
| 2022-11-03 | After-Close | 14.03% | 4.12% | 0.29x | Within |
| 2023-02-21 | After-Close | 12.52% | 2.42% | 0.19x | Within |
| 2023-05-01 | After-Close | 13.27% | 2.66% | 0.20x | Within |
| 2023-08-07 | After-Close | 11.76% | 6.94% | 0.59x | Within |
| 2023-11-06 | After-Close | 11.60% | 2.50% | 0.22x | Within |
| 2024-02-20 | After-Close | 18.09% | 17.47% | 0.97x | Within |
| 2024-04-29 | After-Close | 18.45% | 22.47% | 1.22x | Exceeded |
| 2024-08-05 | After-Close | 23.61% | 2.83% | 0.12x | Within |
| 2024-11-04 | After-Close | 16.08% | 8.45% | 0.53x | Within |
| 2025-02-18 | After-Close | 12.24% | 11.41% | 0.93x | Within |
| 2025-04-28 | After-Close | 12.92% | 0.64% | 0.05x | Within |
| 2025-08-04 | After-Close | 14.62% | 3.26% | 0.22x | Within |
| 2025-11-03 | After-Close | 10.52% | 0.84% | 0.08x | Within |
| 2026-02-17 | After-Close | 5.79% | 0.83% | 0.14x | Within |
| 2026-05-04 | After-Close | 17.64% | 22.48% | 1.27x | Exceeded |
| 2026-08-03 | After-Close | 11.29% | 34.29% | 3.04x | Exceeded |
| 2026-10-26 | Pre-Market | 10.74% | 2.02% | 0.19x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
MED Options Activity & IV Rank
MED IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 44.5%
7-DTE IV: 44.5%
Expected Move: $1.12
7-DTE Move: $0.68
Days to Exp: 35 (2026-12-18)
Options Flow · All expiries
Call Volume: 482
Put Volume: 204
P/C Volume: 0.423
BULLISH
Call OI: 11,504
Put OI: 2,053
P/C OI: 0.178
Total OI: 13,557
ATM Options Pricing
ATM Call: $0.85
ATM Put: $0.28
Call %: 6.6%
Put %: 2.1%
Chain Summary
Chain Volume: 686
Chain OI: 13,557
Last Updated: 11/13/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 22nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
22%
vs own history
GEX tilt
-0.03
OI-weighted, today
Vanna tilt
-0.03
δ-sensitivity to IV
Charm tilt
-0.17
δ-decay vs time
? What is this?
· 6 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Put vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put
—
—
pts
EXTREME
as of Nov 13 · No data
30 DTE / 10d put
—
—
pts
EXTREME
as of Nov 13 · ATM 33.3% / Put —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)5.6LowNov 13
IV Rank (30 DTE)48.9MediumNov 13
Straddle Price (30 DTE)$1.12Nov 13
Beta Analysis
Risk Metrics
Beta: 1.1874
Alpha: 10.57%
Correlation: 0.3013
R-Squared: 9.1%
Stock Volatility: 53.7%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own MED
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $8.3M | #1162 of 3138 | +0.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $598K | #4270 of 6285 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $508K | #3164 of 3716 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $223K | #1769 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
MED Institutional Ownership (13F)
Filings for 2026-06-30 · 47 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 11,061,750 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$25.68M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $9.69M | 37.75% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $5.76M | 22.42% | 2026-06-30 |
| 3 | IMC-Chicago, LLC Custodian | $5.18M | 20.19% | 2026-09-30 |
| 4 | Citadel Advisors LLC Custodian | $2.48M | 9.64% | 2026-06-30 |
| 5 | Walleye Trading LLC | $1.15M | 4.46% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $907.66K | 3.53% | 2026-09-30 |
| 7 | PEAK6 LLC | $333.15K | 1.30% | 2026-06-30 |
| 8 | Walleye Capital LLC | $182.49K | 0.71% | 2026-06-30 |
6 filers$3.73M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | IMC-Chicago, LLC Custodian | $1.92M | 51.47% | 2026-09-30 |
| 2 | Citadel Advisors LLC Custodian | $696.02K | 18.64% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $640.73K | 17.16% | 2026-09-30 |
| 4 | Susquehanna International Group, LLP Custodian | $422.28K | 11.31% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $36.08K | 0.97% | 2026-06-30 |
| 6 | Walleye Capital LLC | $16.98K | 0.45% | 2026-06-30 |
MED Insider Trading (Form 4)
Latest: 2026-11-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-06 | Parsa Kiai | Director | Buy (P) | +661 | $13.03 | $8.6K | EDGAR |
| 2026-10-30 | Parsa Kiai | Director | Buy (P) | +5,557 | $12.24 | $68.0K | EDGAR |
| 2026-09-30 | Daniel R Chard | Director | Sell (S) | −19,089 | $11.85 | -$226.3K | EDGAR |
| 2026-08-28 | Parsa Kiai | Director | Buy (P) | +43,150 | $12.26 | $529.2K | EDGAR |
| 2026-08-26 | Parsa Kiai | Director | Buy (P) | +4,329 | $12.00 | $51.9K | EDGAR |
| 2026-08-21 | Parsa Kiai | Director | Buy (P) | +72,487 | $11.63 | $842.7K | EDGAR |
| 2026-05-28 | Jeffrey Matthew Rose | Director | Award (A) | +18,419 | — | EDGAR | |
| 2026-05-28 | Andrea B Thomas | Director | Award (A) | +11,680 | — | EDGAR | |
| 2026-05-28 | Ming Xian | Director | Grant (A) | +11,680 RSU | — | EDGAR | |
| 2026-05-28 | Elizabeth A. Geary | Director | Award (A) | +11,680 | — | EDGAR | |
| 2026-05-28 | Scott Schlackman | Director | Award (A) | +11,680 | — | EDGAR | |
| 2026-05-28 | Parsa Kiai | Director | Award (A) | +19,317 | — | EDGAR | |
| 2026-05-12 | Scott Schlackman | Director | Buy (P) | +5,000 | $12.59 | $63.0K | EDGAR |
| 2026-03-27 | Jonathan Barrett MacKenzie | VP, Finance & CAO | Mixed Grant +10,830 · Tax −1,130 |
+9,700 | $9.62 | -$10.9K | EDGAR |
| 2026-03-27 | James P. Maloney | Chief Financial Officer | Mixed Tax −4,624 · Grant +35,358 |
+30,734 | $9.64 | -$44.6K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
MED Insider Holdings
10 insiders · @ $12.97
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel R Chard | Chairman & CEO | 346,064 | $4.49M | -$9.43M | 30 | 2026-09-30 |
| 2 | Jeffrey J Brown | Director | 42,810 | $555.3K | -$529.3K | 33 | 2025-06-26 |
| 3 | Scott Schlackman | Director | 42,228 | $547.7K | -$1.56M | 26 | 2026-05-28 |
| 4 | James P. Maloney | Chief Financial Officer | 40,899 | $530.5K | $0 | 13 | 2026-03-27 |
| 5 | Andrea B Thomas | Director | 35,697 | $463.0K | -$190.2K | 15 | 2026-05-28 |
| 6 | Parsa Kiai | Director | 32,769 | $425.0K | $1.50M | 6 | 2026-11-06 |
| 7 | Elizabeth A. Geary | Director | 31,225 | $405.0K | $0 | 4 | 2026-05-28 |
| 8 | Michael A. Hoer | Director | 26,139 | $339.0K | $41.3K | 15 | 2025-06-26 |
| 9 | Jeffrey Matthew Rose | Director | 18,419 | $238.9K | $0 | 1 | 2026-05-28 |
| 10 | Jonathan Barrett MacKenzie | VP, Finance & CAO | 10,008 | $129.8K | $0 | 11 | 2026-03-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
MED Board & Officers
As of SEC filings through Nov 6, 2026Directors 9
- Jeffrey J Brown · since Jun 17, 2015
- Scott Schlackman · since Jun 17, 2015
- Daniel R Chard · since Oct 3, 2016
- Michael A. Hoer · since Jun 13, 2018
- Ming Xian · since Jun 13, 2018
- Andrea B Thomas · since Jun 12, 2019
- Elizabeth A. Geary · since Jun 14, 2023
- Jeffrey Matthew Rose · since May 19, 2026
- Parsa Kiai · since May 19, 2026
Officers 4
- Daniel R Chard · Chairman & CEO · listed since Mar 2021
- Nicholas Mark Johnson · President · since Jan 5, 2026
- James P. Maloney · Chief Financial Officer · since Jul 20, 2020
- Jonathan Barrett MacKenzie · VP, Finance & CAO · since Sep 13, 2021
Changes in the last 10 years (14)
| May 19, 2026 | Parsa Kiai became a director |
| May 19, 2026 | Jeffrey Matthew Rose became a director |
| Jan 5, 2026 | Nicholas Mark Johnson became President |
| Jun 14, 2023 | Elizabeth A. Geary became a director |
| Sep 13, 2021 | Jonathan Barrett MacKenzie became VP, Finance & CAO |
| Mar 19, 2021 | Daniel R Chard listed as Chairman & CEO (previously Chief Executive Officer) in SEC filings |
| Jul 20, 2020 | James P. Maloney became Chief Financial Officer |
| Feb 4, 2020 | Stephen Kyle Johnson became VP, Finance & CAO |
| Jun 12, 2019 | Andrea B Thomas became a director |
| Jun 13, 2018 | Ming Xian became a director |
| Jun 13, 2018 | Michael A. Hoer became a director |
| Feb 9, 2018 | Michael C Macdonald no longer listed as Exec Chairman of the Board in SEC filings |
| Feb 9, 2018 | Joseph P Kelleman first listed as Vice President of Finance in an SEC filing |
| Jan 4, 2017 | Michael C Macdonald listed as Exec Chairman of the Board (previously Chief Executive Officer) in SEC filings |
Not reported recently (11)
- Constance J. Hallquist · Last reported as a director in an SEC filing dated May 11, 2023
- Kevin G Byrnes · Last reported as a director in an SEC filing dated Nov 15, 2021
- Stephen Kyle Johnson · Last reported as VP, Finance & CAO in an SEC filing dated Mar 19, 2021
- Michael C Macdonald · Last reported as a director in an SEC filing dated Oct 2, 2020
- Carl E Sassano · Last reported as a director in an SEC filing dated Jul 22, 2020
- Joseph P Kelleman · Last reported as Vice President of Finance in an SEC filing dated Apr 3, 2020
- Timothy G Robinson · Last reported as Chief Financial Officer in an SEC filing dated Feb 21, 2020
- Charles P Connolly · Last reported as a director in an SEC filing dated Mar 22, 2018
- Glenn W. Welling · Last reported as a director in an SEC filing dated Dec 5, 2017
- Mehrnaz Mona Ameli · Last reported as President, Take Shape For Life in an SEC filing dated Nov 17, 2017
- Jorgene K. Hartwig · Last reported as a director in an SEC filing dated Mar 15, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
MED Proposed Insider Sales (Form 144)
Latest: 2026-09-29
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $226K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Chard Daniel R (2, $226K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-29 | Chard Daniel R | Officer | 9,544 | $112.0K | 2026-09-29 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-28 | Chard Daniel R | Officer | 9,545 | $114.3K | 2026-09-28 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-03-08 | SCOTT SCHLACKMAN | Director | 4,053 | $159.9K | 2024-03-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-08-14 | BROWN JEFFREY J | Director | 38,316 | $3.60M | 2023-08-14 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-26
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
28 ETFs hold MED
25 shown · $38.48M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.00% | $5.6M | — | 2026-09-30 |
| 2 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.02% | $5.2M | $32.8B | 2026-11-12 |
| 3 | VRIG Invesco Variable Rate Investment Grade ETF | Invesco | 0.25% | $5.0M | — | 2026-11-12 |
| 4 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $3.7M | — | 2026-09-30 |
| 5 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.00% | $3.6M | — | 2026-09-30 |
| 6 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.04% | $3.2M | — | 2026-08-31 |
| 7 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.01% | $2.2M | — | 2026-11-12 |
| 8 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.04% | $1.6M | $4.3B | 2026-11-12 |
| 9 | VSS Vanguard FTSE All-World EX-US Small-Cap Index Fund | Vanguard | 0.01% | $1.4M | — | 2026-09-30 |
| 10 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.3M | — | 2026-09-30 |
| 11 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $1.0M | — | 2026-11-12 |
| 12 | VGK Vanguard FTSE Europe ETF | Vanguard | 0.00% | $885,080 | — | 2026-09-30 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.00% | $613,871 | — | 2026-08-31 |
| 14 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.02% | $518,956 | — | 2026-06-30 |
| 15 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.04% | $426,193 | $1.2B | 2026-11-12 |
| 16 | FSCC Federated Hermes MDT Small Cap Core ETF | Nport | 0.12% | $425,094 | — | 2026-08-31 |
| 17 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $338,411 | — | 2026-11-12 |
| 18 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $310,045 | — | 2026-09-30 |
| 19 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $252,570 | — | 2026-11-12 |
| 20 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.01% | $214,672 | $3.3B | 2026-11-12 |
| 21 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $188,811 | — | 2026-11-12 |
| 22 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $129,903 | — | 2026-07-31 |
| 23 | VSGX Vanguard ESG International Stock ETF | Vanguard | 0.00% | $118,087 | — | 2026-11-12 |
| 24 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $116,756 | — | 2026-11-12 |
| 25 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $95,578 | — | 2026-08-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.70
TTM Revenue
$299.57M
TTM Net Income
$-40.85M
TTM Op. Cash Flow
$-26.00K
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $72.05M | $-17.51M | $-1.57 | $3.30M |
| Q2 '26 | 2026-06-30 | $76.38M | $-3.10M | $-0.28 | $1.70M |
| Q1 '26 | 2026-03-31 | $76.04M | $-2.12M | $-0.19 | $260.00K |
| Q4 '25 | 2025-12-31 | $75.10M | $-18.12M | $-1.66 | $-5.28M |
| Q3 '25 | 2025-09-30 | $89.41M | $-2.26M | $-0.21 | $12.11M |
| Q2 '25 | 2025-06-30 | $105.56M | $2.48M | $0.22 | $-3.38M |
| Q1 '25 | 2025-03-31 | $115.73M | $-772.00K | $-0.07 | $3.41M |
| Q4 '24 | 2024-12-31 | $119.00M | $801.00K | $0.07 | $-4.95M |
| Q3 '24 | 2024-09-30 | $140.16M | $1.13M | $0.10 | $9.07M |
| Q2 '24 | 2024-06-30 | $168.56M | $-8.15M | $-0.75 | $13.07M |
| Q1 '24 | 2024-03-31 | $174.74M | $8.32M | $0.76 | $7.28M |
| Q4 '23 | 2023-12-31 | $191.01M | $6.04M | $0.55 | $10.52M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-26
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.73
P/S
0.45
EV/EBITDA
—
EV/Sales
0.22
ROE
-13.0%
ROA
-9.8%
Div Yield
0.12%
FCF Yield
6.15%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$142.85M
as of 2026-11-13
MED vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AHR American Healthcare REIT, Inc. | $13.6B | 117.9 | +21.5% | +22.3% | 56 |
| CNO CNO Financial Group, Inc. | $5.2B | 19.7 | +6.0% | +36.2% | 64 |
| SPHR Sphere Entertainment Co. | $4.5B | — | +29.9% | +33.1% | 37 |
| BKU Bankunited, Inc. | $3.1B | 12.0 | −5.2% | −2.1% | 11 |
| SLDE Slide Insurance Holdings, Inc. Common St | $3.0B | 6.3 | +41.5% | +38.8% | 33 |
| SPSC SPS Commerce, Inc. | $2.9B | 36.0 | +6.9% | −7.5% | 27 |
| BY Byline Bancorp, Inc. Common Stock | $1.7B | 11.8 | +2.3% | +35.0% | 33 |
| PSTL Postal Realty Trust, Inc | $759M | 41.4 | +22.3% | +38.6% | 90 |
| MED Medifast, Inc. | $144M | — | −30.3% | +24.7% | 49 |
| Peer median | $3.1B | 19.7 | +14.2% | +34.1% | 35 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.30M
SI % of Float
13.01%
Days to Cover
8.24
Short Vol Ratio
59.3%
Free Float
9.97M
Float %
89.2%
Short interest 2026-10-30 • Short volume 2026-11-13 • Float 2026-08-21